A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene

We describe a Sanger sequencing protocol for SARS‐CoV‐2 S‐gene the Spike (S)‐glycoprotein product of which, composed of receptor‐binding (S1) and membrane fusion (S2) segments, is the target of vaccines used to combat COVID‐19. The protocol can be used in laboratories with basic Sanger sequencing ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniels, Rodney S., Harvey, Ruth, Ermetal, Burcu, Xiang, Zheng, Galiano, Monica, Adams, Lorin, McCauley, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447197/
https://www.ncbi.nlm.nih.gov/pubmed/34346163
http://dx.doi.org/10.1111/irv.12892
Descripción
Sumario:We describe a Sanger sequencing protocol for SARS‐CoV‐2 S‐gene the Spike (S)‐glycoprotein product of which, composed of receptor‐binding (S1) and membrane fusion (S2) segments, is the target of vaccines used to combat COVID‐19. The protocol can be used in laboratories with basic Sanger sequencing capabilities and allows rapid “at source” screening for SARS‐CoV‐2 variants, notably those of concern. The protocol has been applied for surveillance, with clinical specimens collected in either nucleic acid preservation lysis‐mix or virus transport medium, and research involving cultured viruses, and can yield data of public health importance in a timely manner.

Ejemplares similares